A genotype-guided strategy for deciding on antiplatelet agents after PCI does not lead to improvements in long-term ischemic events, according to extended follow-up from TAILOR-PCI. The results are in ...

The results of a large network meta-analysis throw additional support for a paradigm shift in how dual antiplatelet therapy (DAPT) should be maintained after PCI with drug-eluting stents, researchers ...

Originally created to offer a standardized way to improve data rates between processors and peripheral chips, HyperTransport will soon include protocols for a bevy of networking and telecommunication ...

Extended treatment with dual antiplatelet therapy reduced the risk of ischemic events and bleeding after PCI in patients with and without peripheral arterial disease, according to findings presented ...

AMSTERDAM -- Two trials from Asia weighed in on reducing components and duration of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) but with questionable applicability ...

WASHINGTON, D.C, (April 28, 2021) - An analysis of the prospective Fuwai PCI Registry, confirms long-term dual antiplatelet therapy (DAPT) is an optimal treatment option for acute coronary syndrome ...

The observational extended study of the previously reported 12-month randomized TAILOR-PCI trial shows genotype-guided antiplatelet therapy after percutaneous coronary intervention (PCI) did not ...